Gerald Schwank obtained his PhD at the University of Zurich in 2009. As a postdoctoral fellow he joined the team of Hans Clevers at the Hubrecht Institute, where he established genome editing approaches in adult stem cells. In 2014 he started his own laboratory at ETH Zurich, where his team developed CRISPR-based genetic tools to study human disease mechanisms. More recently the Schwank laboratory shifted its focus on the development of in vivo genome editing approaches to cure genetic diseases of the liver and brain. In 2020 Gerald Schwank was appointed as Associate Professor at the University of Zurich, where he and his team continue to pursue their goal of generating novel genome editors and translating these technologies from bench to bedside.